For the quarter ending 2025-09-30, EMMA had -$592K decrease in cash & cash equivalents over the period. $409K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -2,076 | -3,465 |
| Depreciation and amortization | 15 | 9 |
| Inventory reserve | 4 | -4 |
| Amortization of discount of notes payable and convertible notes payable | 142 | 227 |
| Foreign exchange adjustments | 72 | -211 |
| Tax benefit recognized on unrealized gain on debt securities | -578 | 591 |
| Realized loss on investment in convertible bond | 0 | -531 |
| Loss on debt extinguishment | -296 | -376 |
| Gain on lease modification | 0 | 861 |
| Share-based compensation | 9 | 9 |
| Change in fair value of warrant derivative liabilities | 2 | -5 |
| Change in fair value of conversion feature derivative, notes payable | 0 | 162 |
| Accounts receivable | 548 | -552 |
| Inventories | -109 | -319 |
| Prepaid expenses and other current assets | -84 | -376 |
| Other non-current assets | -31 | -302 |
| Accounts payable and accrued expenses | 2,414 | 2,464 |
| Other current liabilities | -166 | -2,516 |
| Other long-term liabilities | -401 | -419 |
| Net cash flows used in operating activities | 409 | -2,629 |
| Proceeds from sale of convertible bond | 0 | 2,172 |
| Purchases of property and equipment | 0 | 1 |
| Net cash flows provided by investing activities | 0 | 2,171 |
| Proceeds from notes payable issued | 1,324 | 3,238 |
| Payments of notes payable | 2,326 | 2,849 |
| Payments of notes payable, related party | 0 | 240 |
| Payments of convertible notes | 0 | 210 |
| Net cash flows used in financing activities | -1,002 | -61 |
| Effect of exchange rate changes on cash | 1 | 15 |
| Net decrease in cash and cash equivalents | -592 | -504 |
| Cash and cash equivalents at beginning of period | 1,389 | - |
| Cash and cash equivalents at end of period | 293 | - |
Emmaus Life Sciences, Inc. (EMMA)
Emmaus Life Sciences, Inc. (EMMA)